Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from  days prior to the dose of study medication and during the entire study; orange juice is allowed
Participants receiving any medications or substances that are moderate and strong inhibitors or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA), including enzyme-inducing anti-epileptic drugs (EIAEDs) within  days before the first dose of ponatinib will be excluded; this category includes phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, and oxcarbazepine\r\n* NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from  days prior to the first dose of study drug and during the entire study treatment period
Participant consumed grapefruit or grapefruit products within  days prior to the first dose of study drug.
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study.
For subjects in expansion cohort only: Ingestion of any food or drink containing grapefruit or Seville oranges, or St. Johns wort, within  days prior to receiving the first dose of AMG 
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study
Patients must avoid consumption of grapefruit, pomegranates, starfruit, Seville oranges or products containing the juice of each during the entire study and preferably  days before the first dose of study medications; orange juice is allowed
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study, as these may affect selumetinib metabolism
Consumption of grapefruit and related fruits within  days prior to initiation of study drug
Use of strong or moderate inhibitors and inducers of cytochrome P (CYP) A, including certain herbal medications (eg, St. John's Wort) and consumption of grapefruit or grapefruit juice within  days or  x the half?life (whichever is longer) prior to the first dose of study drug.
Patients must avoid grapefruit, grapefruit juice, supplements containing grapefruit juice, star fruit, and Seville oranges during the entire study, starting  days prior to the first dose of study drug
Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice, pommelos, or exotic citrus fruits, from  day prior to the first dose of study treatment(s) until the last dose of study drug
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study
Consumption of grapefruit, grapefruit juice, pomegranates, star fruits, Seville oranges or products within  days prior to first dose
Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from  days prior to the dose of study medication and during the entire study; NOTE: orange juice is allowed
Consumption of grapefruit, grapefruit juice, grapefruit hybrids, pomelos, pomegranates, star fruits, Seville oranges or related products within  days prior to first dose
Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from  days prior to the dose of study medication, throughout the study, and until  weeks after the last dose of AZD due to potential cytochrome P, family , subfamily A, polypeptide  (CYPA) interaction with the study medication; orange juice is allowed
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
Grapefruit-containing food or beverages within  days before the first dose of study drug. Note that grapefruit-containing food and beverages are not permitted during the study.
Patients currently taking warfarin, tamoxifen, phenytoin, diclofenac, tolbutamide, or ibuprofen are excluded secondary to potential inhibition of cytochrome P C (CYPC); in addition patients that consume grapefruit juice and Seville orange juice must not consume these during the study
Participants taking a drug known to be strong inhibitors or inducers of isoenzyme CYPA; participant must be off CYPA inhibitors and inducers for at least  days prior to planned start of study treatment; NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from  days prior to planned start of study treatment and during the entire study treatment period due to potential CYPA interaction
Is willing to abstain from grapefruit and Seville oranges (or juice) from  days before the first dose until study completion
Participants taking a drug known to be a strong inhibitor or inducer of isoenzyme CYPA; participant must be off CYPA inhibitors and inducers for at least  days prior to starting study drug; NOTE: participants must avoid consumption of Seville oranges (and juice), grapefruits or grapefruit juice, grapefruit hybrids, pomelos and exotic citrus fruits from  days prior to the first dose of study drug and during the entire study treatment period
Patients must not be taking ketoconazole, dexamethasone, the dysrhythmic drugs (terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, indapamide or flecainide), haloperidol, risperidone, rifampin, grapefruit, or grapefruit juice within two weeks of randomization and during the course of therapy; topical and inhaled steroids are permitted
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
Is unwilling to exclude grapefruit juice, Seville oranges, and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment throughout their time on study
Participants unwilling to exclude grapefruit juice and grapefruit from their diet.
Grapefruit, Seville oranges or products containing either juice
Grapefruit, grapefruit juice, and other foods known to inhibit cytochrome P and PgP activity may increase everolimus exposures and should be avoided during treatment.
Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice, pommelos, or exotic citrus fruits, from  day prior to the first dose of study treatment(s) until the last dose of study drug.
Patients must not eat grapefruit or drink grapefruit juice or plan to eat or drink them during study therapy
Patients should avoid CYPA inhibiting foods including grapefruit and Seville orange juice
Have taken certain medications or had grapefruit juice within  days of initial dose of study drug, as levels of the study drug may be affected.
Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pomelos, and exotic citrus fruits from  days prior to the dose of study medication and during the entire study due to potential cytochrome P A (CYPA) interaction with the study medication; orange juice is allowed
Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice, pommelos, or exotic citrus fruits, from  day prior to the first dose of study treatment(s) until the last dose of study drug.
Grapefruit juice (potent cytochrome P CYPA enzyme inhibitor).
RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients must agree to avoid grapefruit or grapefruit juice and Seville (sour) oranges during the entire study
NON-PROGRESSED DIPG (STRATUM ): Patients must agree to avoid grapefruit or grapefruit juice and Seville (sour) oranges during the entire study
Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within  days prior to day 
Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within  days prior to day  and during the study
Consumption of food or beverages containing grapefruit juice within  days of study drug dosing
Subject has consumed grapefruit or grapefruit products within  days prior to the first dose of study drug
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study, as these may affect selumetinib metabolism
Willing to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Patients should agree to avoid grapefruit juice which is a major inhibitor of cytochrome P- (CYP)A
Must abstain from grapefruit juice
Grapefruit-containing food or beverages within  days before the first dose of study drug. Note that grapefruit-containing food and beverages are not permitted during the study.
Willingness to refrain from grapefruit juice for  days prior to and for  days during the study
Consumption of grapefruit or grapefruit juice is not permitted during the study; patients should not consume food or beverages containing the fruit or juice of grapefruits or Seville oranges within  days before the first dose of study drug and throughout the study
Consumed grapefruit juice or grapefruit containing products within  days of the first planned ranolazine dose
Participants who have taken any medicines that are inducers, inhibitors or substrates of select cytochrome (CYP) isozymes within the past  months will be excluded; participants who have consumed either grapefruit juice or Seville orange juice in the past  days will be excluded
Willingness to abstain from grapefruit juice, alcohol, and concomitant medications during study
Food or beverages containing grapefruit within  days before the first dose of study drug. Note that food and beverages containing grapefruit are not permitted during the study.
Grapefruit-containing food or beverages within  days before the first dose of study drug. Note that grapefruit-containing food and beverages are prohibited during the study.
